Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Publication
, Journal Article
Bohula, EA; Giugliano, RP; Cannon, CP; Zhou, J; Murphy, SA; White, J; Tershakovec, AM; Blazing, MA; Braunwald, E
Published in: Circulation
March 29, 2016
Duke Scholars
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
March 29, 2016
Volume
133
Issue
13
Start / End Page
e463
Location
United States
Related Subject Headings
- Simvastatin
- Male
- Humans
- Female
- Ezetimibe
- Cholesterol, LDL
- Cardiovascular System & Hematology
- C-Reactive Protein
- Anticholesteremic Agents
- Acute Coronary Syndrome
Citation
APA
Chicago
ICMJE
MLA
NLM
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J., … Braunwald, E. (2016). Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation, 133(13), e463. https://doi.org/10.1161/CIRCULATIONAHA.116.020947
Bohula, Erin A., Robert P. Giugliano, Christopher P. Cannon, Jing Zhou, Sabina A. Murphy, Jennifer White, Andrew M. Tershakovec, Michael A. Blazing, and Eugene Braunwald. “Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".” Circulation 133, no. 13 (March 29, 2016): e463. https://doi.org/10.1161/CIRCULATIONAHA.116.020947.
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White J, et al. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29;133(13):e463.
Bohula, Erin A., et al. “Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".” Circulation, vol. 133, no. 13, Mar. 2016, p. e463. Pubmed, doi:10.1161/CIRCULATIONAHA.116.020947.
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White J, Tershakovec AM, Blazing MA, Braunwald E. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29;133(13):e463.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
March 29, 2016
Volume
133
Issue
13
Start / End Page
e463
Location
United States
Related Subject Headings
- Simvastatin
- Male
- Humans
- Female
- Ezetimibe
- Cholesterol, LDL
- Cardiovascular System & Hematology
- C-Reactive Protein
- Anticholesteremic Agents
- Acute Coronary Syndrome